Psychosis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Psychosis - Pipeline Review, H2 2016

Psychosis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Psychosis - Pipeline Review, H2 2016
Published Oct 29, 2016
70 pages — Published Oct 29, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psychosis Pipeline Review, H2 2016, provides an overview of the Psychosis (Central Nervous System) pipeline landscape.

Psychosis is a serious mental disorder characterized by thinking and emotions that are so impaired, that they indicate that the person experiencing them has lost contact with reality. Psychotic symptoms include disorganized thought, speech or behavior, disordered thinking (jumping between unrelated topics, making strange connections between thoughts), Catatonia (unresponsiveness). Treatment includes antipsychotic drugs, which reduce hallucinations and delusions and improve thinking and behavior are helpful, whether the cause is a medical or psychiatric disorder.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psychosis Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Psychosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psychosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Psychosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 15 and 1 respectively for Psychosis.

Psychosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Psychosis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Psychosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Psychosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Psychosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to p

  
Source:
Document ID
GMDHC8601IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Psychosis Overview81
Therapeutics Development91
  Pipeline Products for Psychosis Overview91
Psychosis Therapeutics under Development by Companies101
Psychosis Pipeline Products Glance112
  Clinical Stage Products111
  Early Stage Products121
Psychosis Products under Development by Companies131
Psychosis Companies Involved in Therapeutics Development1412
  Acadia Pharmaceuticals Inc.141
  Addex Therapeutics Ltd151
  Evotec AG161
  Gabather AB171
  Glenmark Pharmaceuticals Ltd.181
  Heptares Therapeutics Limited191
  Integrative Research Laboratories Sweden AB201
  Merck &Co., Inc.211
  Newron Pharmaceuticals S.p.A.221
  Reviva Pharmaceuticals Inc.231
  Sumitomo Dainippon Pharma Co., Ltd.241
  Sunovion Pharmaceuticals Inc.251
Psychosis Therapeutics Assessment267
  Assessment by Monotherapy Products261
  Assessment by Target272
  Assessment by Mechanism of Action292
  Assessment by Route of Administration311
  Assessment by Molecule Type321
Drug Profiles3327
  ADX-88178 Drug Profile332
  CB-0306 Drug Profile351
  Drug to Agonize Muscarinic M4 Receptors for Psychiatric Diseases and Alzheimer's Disease Drug Profile361
  evenamide Drug Profile373
  GT-001 Drug Profile401
  GT-002 Drug Profile411
  GT-004 Drug Profile421
  GT-006 Drug Profile431
  HUF-101 Drug Profile441
  IRL-790 Drug Profile451
  pimavanserin tartrate Drug Profile465
  RP-5063 Drug Profile512
  SEP-39 Drug Profile531
  Small Molecule for Psychosis Drug Profile541
  Small Molecule to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases Drug Profile551
  Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis Drug Profile561
  Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis Drug Profile571
  Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis Drug Profile581
  Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis Drug Profile591
Psychosis Dormant Projects601
Psychosis Discontinued Products611
Psychosis Product Development Milestones627
  Featured News &Press Releases621
    May 31, 2016: ACADIA Pharmaceuticals Announces NUPLAZID (pimavanserin) Is Now Available for the Treatment of Hallucinations and Delusions Associated with Parkinson s Disease Psychosis621
    Apr 29, 2016: FDA approves first drug to treat hallucinations and delusions associated with Parkinson s disease621
    Mar 29, 2016: FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals NUPLAZID(Pimavanserin) for the Treatment of Psychosis Associated with Parkinson s Disease Outweigh the Risks631
    Jan 29, 2016: ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting to Review NUPLAZID(Pimavanserin) for the Treatment of Parkinson s Disease Psychosis641
    Nov 17, 2014: Heptares First-In-Class Selective Muscarinic Agonists Chosen As One Of Top Neuroscience Projects To Watch641
    Sep 02, 2014: Acadia Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID (Pimavanserin) for Parkinson s Disease Psychosis651
    Aug 28, 2014: ACADIA Pharmaceuticals Announces Trade Name NUPLAZID for Pimavanserin651
    Apr 14, 2010: Joseph Friedman To Present Data From ACADIA's First Phase III Trial With Pimavanserin For PDP At 62nd American Academy Of Neurology Annual Meeting661
    Sep 01, 2009: ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis671
    May 06, 2009: ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis671
    Jun 11, 2007: ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis681
Appendix692
  Methodology691
  Coverage691
  Secondary Research691
  Primary Research691
  Expert Panel Validation691
  Contact Us691
  Disclaimer701

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Psychosis - Pipeline Review, H2 2016" Oct 29, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Psychosis-Pipeline-Review-H2-2016-2088-16717>
  
APA:
Global Markets Direct - Market Research. (2016). Psychosis - Pipeline Review, H2 2016 Oct 29, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Psychosis-Pipeline-Review-H2-2016-2088-16717>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.